FindTrial
Sign In

HDtDCS primed iTBS in Treatment Resistant Depression.

HIGH-DEFINITON TRANSCRANIAL DIRECT CURRENT STIMULATION PRIMED THETA BURST STIMULATION IN TREATMENT RESISTANT DEPRESSION AS MEASURED BY NERVE GROWTH FACTOR: A RANDOMISED SHAM-CONTROLLED STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/034656
Enrollment
40
Registered
2021-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F30-F39- Mood [affective] disorders

Interventions

Intervention1: High Definition Transcranial Direct Current Stimulation primed Theta Burst Stimulation: Treatment Resistant Depression patients will be randomly divided into active and control groups.

Sponsors

Central Institute of Psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Depression using Diagnostic Criteria for Research (DCR) of International Classification of Disease-10th edition (ICD-10, World Health Organization,1993) 2. Age between 18- 60 years of either sex 3. The Hamilton Rating Scale for Depression-17 score of at least 18. 4. No response to at least two separate trials of antidepressants of adequate dose and duration. 5. Right-handed. 6. Patients giving written informed consent.

Exclusion criteria

Exclusion criteria: 1. Lifetime history of non-response to an adequate ECT trial (minimum of 8 sessions). 2. Patient with co morbid active substance dependence in the last 6 months, except nicotine and caffeine. 3. Suicidal intent or any psychiatric emergency. 4. Pregnancy 5. Patients with active psychotic symptoms. 6. Cardiac Pacemaker or Intracranial implant. 7. Neurological comorbidity that could substantially influence depression. 8. Unstable medical illness 9. Patients who have been co prescribed BZD >1mg Clonazepam equivalent or anti-epileptic drugs.

Design outcomes

Primary

MeasureTime frame
Improvement in depressive symptoms as measured by the Hamilton Depression Rating Scale (HAM-D) and Clinical Global Impression Scale (CGI) after 2 weeks of HDtDCS primed iTBS in patients of Treatment Resistant Depression.Timepoint: Improvement in depressive symptoms as measured by the Hamilton Depression Rating Scale (HAM-D) and Clinical Global Impression Scale (CGI) after 2 weeks of HDtDCS primed iTBS in patients of Treatment Resistant Depression.—

Secondary

MeasureTime frame
Changes in Nerve Growth Factor levels in the serum measured using ELISA kits after treatment with HDtDCS primed iTBS.Timepoint: Baseline-T1 1 week- T2 2 weeks- T3 4 weeks- T4—

Countries

India

Contacts

Public ContactDr Nishant Goyal

Central Institute of Psychiatry

psynishant@gmail.com9431171162

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026